HPV16 DNA Rinse Post Treatment Could Predict Recurrence

Share this content:
Human papillomavirus type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma.
Human papillomavirus type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma.

Human papillomavirus (HPV) type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma (OPC).

A study published online ahead of print in JAMA Oncology found a link between persistent HPV16 DNA in post-treatment oral rinses and poor prognosis.

Although infrequent, the rinse can potentially be a tool for long-term tumor surveillance, according to the study.

HPV-OPC incidence rates are increasing in the United States. Prognosis is typically favorable, however it has a 10% to 25% recurrence rate. Researchers evaluated whether HPV DNA detection in oral rinses post-treatment was associated with recurrence and survival.

Patients with HPV-OPC diagnosed between 2009 and 2013 were included in the study and samples were collected post treatment at 9, 12, 18, and 24 months following diagnosis. A total of 124 patients had one or more oral rinses available and were included.

Researchers found that at diagnosis, HPV16 DNA was present in 54% of samples. Post treatment, however, it was detected in six participants (5%), five of whom in which it was also detected at diagnosis. Two-year disease-free survival and overall survival rates were 92% and 98%, respectively.

RELATED: High Heregulin mRNA, HER3 Linked to Poor Survival in Oropharyngeal Carcinoma

Persistent HPV16 DNA was associated with worse disease-free survival and overall survival. All participants with persistent HPV16 DNA developed recurrent disease.

However 9 of 119 participants (8%) without persistent HPV16 DNA developed recurrent disease.

Reference

  1. Rettig EM, Wentz A, Posner MR, et al. Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus-related oropharyngeal carcinoma. JAMA Oncol. 2015. [epub ahead of print]. doi:10.1001/jamaoncol.2015.2524.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters